In July 2016, Zimmer Biomet Holdings (ZBH) acquired LDR Holdings for around $1 billion, which helped strengthen the company’s spine business. It’s been one year since the acquisition, and the company has almost completed the commercial integration of LDR Holdings with the Zimmer Biomet Holdings and expects to begin capitalizing on the cross-selling opportunities. The sales channel integration is a key part of the process. The LDR acquisition contributed around 2.4% to the sales growth in 2Q17.
For details at the time of the acquisition, read Zimmer Biomet to Strengthen its Spine Business through LDR Acquisition.
Spine business product portfolio and future outlook
With the acquisition of LDR Holdings, Zimmer Biomet Holdings acquired its market-leading Mobi-C CDR (cervical disc replacement) device. The product continues to generate significant demand in the market, boosting Zimmer Biomet Holding’s spine sales. The Vitality Spinal Fixation System, SternaLock Blu, SternaLock 360 primary closure systems, and the RibFix Blu Thoracic Fixation System are some of the other key products under the company’s Spine & CMF business segment that continue to show strong growth momentum. However, the product portfolio except non-Mobi-C has been facing some challenges through the integration due to the dis-synergies in channel integration. Zimmer Biomet Holdings expects its expanded spine business to register growth in 4Q17 and continue the growth momentum into 2018. To expand its spine business, Zimmer Biomet Holdings also acquired MedTech recently, which manufactures robotics technologies for brain and spine surgeries.
As per the company, the global spine market is worth $10 billion. Zimmer Biomet Holdings is one of the leading players in this market. With the completion of the integration of the LDR Holdings, it is further expected to register accelerated growth across the market segment as the company now offers a comprehensive spine portfolio. Major competitors of Zimmer Biomet Holdings in this market segment include Medtronic (MDT), Depuy Synthes, a subsidiary of Johnson & Johnson (JNJ), and Stryker (SYK).
For exposure to Zimmer Biomet Holdings, while diversifying the company-specific and industry-specific risks, investors can invest in the iShares Russell Mid-Cap Value ETF (IWS). IWS holds ~0.62% of its total holdings in ZBH.
Zimmer Biomet Holdings (ZBH) has fallen around 0.8% over the last one week.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.